Angiotensin II blockade in kidney transplant recipients

Hassan N Ibrahim, Scott Jackson, Jeffery Connaire, Arthur J Matas, Arthur Ney, Behzad Najafian, Ann West, Nicole Lentsch, Jensina Ericksen, Jenny Bodner, Bert L Kasiske, Michael Mauer

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Interstitial fibrosis/tubular atrophy (IF/TA) contributes to the loss of kidney allografts, and treatment or preventive options are lacking. We conducted a double-blind, randomized, placebo-controlled trial to determine whether angiotensin II blockade prevents the expansion of the cortical interstitial compartment, the precursor of fibrosis. We randomly assigned 153 transplant recipients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantation, continuing treatment for 5 years. The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA. In the intention-to-treat analysis, using only patients with adequate structural data, the primary endpoint occurred in 6 of 47 patients who received losartan and 12 of 44 who received placebo (odds ratio [OR], 0.39; 95%confidence interval [CI], 0.13-1.15; P=0.08).We found no significant effect of losartan on time to a composite of ESRD, death, or doubling of creatinine level. In a secondary analysis, losartan seemed to reduce the risk of a composite of doubling of interstitial volume or all-cause ESRD (OR, 0.36; 95% CI, 0.13-0.99; P=0.05), but this finding requires validation. In conclusion, treatment with losartan did not lead to a statistically significant reduction in a composite of interstitial expansion or ESRD from IF/TA in kidney transplant recipients.

Original languageEnglish (US)
Pages (from-to)320-327
Number of pages8
JournalJournal of the American Society of Nephrology
Volume24
Issue number2
DOIs
StatePublished - Jan 31 2013

Fingerprint

Losartan
Angiotensin II
Chronic Kidney Failure
Kidney
Fibrosis
Atrophy
Placebos
Odds Ratio
Confidence Intervals
Intention to Treat Analysis
Allografts
Creatinine
Therapeutics
Randomized Controlled Trials
Transplantation
Transplant Recipients

Cite this

Angiotensin II blockade in kidney transplant recipients. / Ibrahim, Hassan N; Jackson, Scott; Connaire, Jeffery; Matas, Arthur J; Ney, Arthur; Najafian, Behzad; West, Ann; Lentsch, Nicole; Ericksen, Jensina; Bodner, Jenny; Kasiske, Bert L; Mauer, Michael.

In: Journal of the American Society of Nephrology, Vol. 24, No. 2, 31.01.2013, p. 320-327.

Research output: Contribution to journalArticle

Ibrahim, HN, Jackson, S, Connaire, J, Matas, AJ, Ney, A, Najafian, B, West, A, Lentsch, N, Ericksen, J, Bodner, J, Kasiske, BL & Mauer, M 2013, 'Angiotensin II blockade in kidney transplant recipients', Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 320-327. https://doi.org/10.1681/ASN.2012080777
Ibrahim, Hassan N ; Jackson, Scott ; Connaire, Jeffery ; Matas, Arthur J ; Ney, Arthur ; Najafian, Behzad ; West, Ann ; Lentsch, Nicole ; Ericksen, Jensina ; Bodner, Jenny ; Kasiske, Bert L ; Mauer, Michael. / Angiotensin II blockade in kidney transplant recipients. In: Journal of the American Society of Nephrology. 2013 ; Vol. 24, No. 2. pp. 320-327.
@article{e5e832c7b9b04059ab3208dd7cb58bc8,
title = "Angiotensin II blockade in kidney transplant recipients",
abstract = "Interstitial fibrosis/tubular atrophy (IF/TA) contributes to the loss of kidney allografts, and treatment or preventive options are lacking. We conducted a double-blind, randomized, placebo-controlled trial to determine whether angiotensin II blockade prevents the expansion of the cortical interstitial compartment, the precursor of fibrosis. We randomly assigned 153 transplant recipients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantation, continuing treatment for 5 years. The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA. In the intention-to-treat analysis, using only patients with adequate structural data, the primary endpoint occurred in 6 of 47 patients who received losartan and 12 of 44 who received placebo (odds ratio [OR], 0.39; 95{\%}confidence interval [CI], 0.13-1.15; P=0.08).We found no significant effect of losartan on time to a composite of ESRD, death, or doubling of creatinine level. In a secondary analysis, losartan seemed to reduce the risk of a composite of doubling of interstitial volume or all-cause ESRD (OR, 0.36; 95{\%} CI, 0.13-0.99; P=0.05), but this finding requires validation. In conclusion, treatment with losartan did not lead to a statistically significant reduction in a composite of interstitial expansion or ESRD from IF/TA in kidney transplant recipients.",
author = "Ibrahim, {Hassan N} and Scott Jackson and Jeffery Connaire and Matas, {Arthur J} and Arthur Ney and Behzad Najafian and Ann West and Nicole Lentsch and Jensina Ericksen and Jenny Bodner and Kasiske, {Bert L} and Michael Mauer",
year = "2013",
month = "1",
day = "31",
doi = "10.1681/ASN.2012080777",
language = "English (US)",
volume = "24",
pages = "320--327",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Angiotensin II blockade in kidney transplant recipients

AU - Ibrahim, Hassan N

AU - Jackson, Scott

AU - Connaire, Jeffery

AU - Matas, Arthur J

AU - Ney, Arthur

AU - Najafian, Behzad

AU - West, Ann

AU - Lentsch, Nicole

AU - Ericksen, Jensina

AU - Bodner, Jenny

AU - Kasiske, Bert L

AU - Mauer, Michael

PY - 2013/1/31

Y1 - 2013/1/31

N2 - Interstitial fibrosis/tubular atrophy (IF/TA) contributes to the loss of kidney allografts, and treatment or preventive options are lacking. We conducted a double-blind, randomized, placebo-controlled trial to determine whether angiotensin II blockade prevents the expansion of the cortical interstitial compartment, the precursor of fibrosis. We randomly assigned 153 transplant recipients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantation, continuing treatment for 5 years. The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA. In the intention-to-treat analysis, using only patients with adequate structural data, the primary endpoint occurred in 6 of 47 patients who received losartan and 12 of 44 who received placebo (odds ratio [OR], 0.39; 95%confidence interval [CI], 0.13-1.15; P=0.08).We found no significant effect of losartan on time to a composite of ESRD, death, or doubling of creatinine level. In a secondary analysis, losartan seemed to reduce the risk of a composite of doubling of interstitial volume or all-cause ESRD (OR, 0.36; 95% CI, 0.13-0.99; P=0.05), but this finding requires validation. In conclusion, treatment with losartan did not lead to a statistically significant reduction in a composite of interstitial expansion or ESRD from IF/TA in kidney transplant recipients.

AB - Interstitial fibrosis/tubular atrophy (IF/TA) contributes to the loss of kidney allografts, and treatment or preventive options are lacking. We conducted a double-blind, randomized, placebo-controlled trial to determine whether angiotensin II blockade prevents the expansion of the cortical interstitial compartment, the precursor of fibrosis. We randomly assigned 153 transplant recipients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantation, continuing treatment for 5 years. The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA. In the intention-to-treat analysis, using only patients with adequate structural data, the primary endpoint occurred in 6 of 47 patients who received losartan and 12 of 44 who received placebo (odds ratio [OR], 0.39; 95%confidence interval [CI], 0.13-1.15; P=0.08).We found no significant effect of losartan on time to a composite of ESRD, death, or doubling of creatinine level. In a secondary analysis, losartan seemed to reduce the risk of a composite of doubling of interstitial volume or all-cause ESRD (OR, 0.36; 95% CI, 0.13-0.99; P=0.05), but this finding requires validation. In conclusion, treatment with losartan did not lead to a statistically significant reduction in a composite of interstitial expansion or ESRD from IF/TA in kidney transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=84873362249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873362249&partnerID=8YFLogxK

U2 - 10.1681/ASN.2012080777

DO - 10.1681/ASN.2012080777

M3 - Article

C2 - 23308016

AN - SCOPUS:84873362249

VL - 24

SP - 320

EP - 327

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 2

ER -